![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Brown University University of Maryland Greenebaum Cancer Center |
---|---|
Information provided by: | Brown University |
ClinicalTrials.gov Identifier: | NCT00522795 |
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer |
Drug: Paclitaxel Poliglumex and Cisplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001 |
Estimated Enrollment: | 32 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
32 patients with esophageal or gastroesophageal junction cancer will receive Radiation:50.4 Gy at 180cGy fraction/day for 28 treatments and Paclitaxel Poliglumex (PPX) and Cisplatin weekly times 6 followed by surgery.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Teresa a kennedy, RN, CCRA | 401-383-3000 | Teresa_Kennedy@Brown.edu |
United States, Rhode Island | |
Lifespan Hospitals | Recruiting |
Providence, Rhode Island, United States, 02903 | |
Contact: Teresa A Kennedy, RN 401-383-3000 Teresa_Kennedy@brown.edu | |
Principal Investigator: Howard safran, MD |
Principal Investigator: | Howard Safran, MD | Brown University |
Responsible Party: | Brown University Oncology Group ( Howard Safran,MD ) |
Study ID Numbers: | BrUOG-E-215 |
Study First Received: | August 28, 2007 |
Last Updated: | July 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00522795 |
Health Authority: | United States: Food and Drug Administration |
Esophageal Cancer |
Digestive System Neoplasms Digestive System Diseases Cisplatin Esophageal disorder Paclitaxel Gastrointestinal Diseases |
Head and Neck Neoplasms Esophageal Neoplasms Gastrointestinal Neoplasms Esophageal Diseases Esophageal neoplasm |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Radiation-Sensitizing Agents Antineoplastic Agents Therapeutic Uses |
Mitosis Modulators Tubulin Modulators Physiological Effects of Drugs Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |